

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Shares thereby offered.*

*This announcement is not for release, publication, and distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of an offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The Offer Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”), or any state securities laws of the United States, and may not be offered, sold, pledged or transferred or delivered within the United States unless pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act or any state securities laws of the United States. The Offer Shares may only be offered and sold outside of the United States in offshore transactions in accordance with Regulation S under the U.S. Securities Act. The Company has not intended and does not intend to make any public offer of securities in the United States.*



**Akeso, Inc.**

**康方生物科技(開曼)有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 9926)**

## **CLARIFICATION ANNOUNCEMENT**

Reference is made to the prospectus of Akeso, Inc. (the “**Company**”) dated April 14, 2020 (the “**Prospectus**”) and the Application Forms. All capitalised terms used in this announcement shall have the same meanings as those defined in the Prospectus. This clarification announcement is published for the purpose of correcting the inadvertent clerical error on page 7 of the **WHITE** Application Forms clarifying the relevant disclosure therein as explained below.

Whilst the corresponding English section on page 5 of the WHITE Application Forms is correct, on page 7 of the WHITE Application Forms, the third column in the table headed “可供申請認購股份數目及應繳款項” should be replaced with the following:

申請認購的香港發售股份數目	申請時應繳款項 港元
100,000	1,634,304.59
150,000	2,451,456.88
200,000	3,268,609.17
250,000	4,085,761.47
300,000	4,902,913.76
350,000	5,720,066.05
400,000	6,537,218.34
450,000	7,354,370.64
500,000	8,171,522.93
600,000	9,805,827.52
700,000	11,440,132.10

Whilst the Hong Kong Public Offering has started from 9:00 a.m. on Tuesday, April 14, 2020, the revised version of WHITE Application Forms will be available during normal business hours as early as 9:00 a.m. from Wednesday, April 15, 2020 at the addresses of the Hong Kong Underwriters and the applicable branches of the receiving banks as disclosed in the subsection of the Prospectus headed “How To Apply for the Hong Kong Offer Shares — 3. Applying for Hong Kong Offer Shares which Application Channel to Use”.

The revised version of WHITE Application Form identified with a black triangle marked to the top right corner on the first page will be published on the websites of the Company at [www.akesobio.com](http://www.akesobio.com) and the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) as soon as practicable.

The offer period shall remain unchanged, being from 9: 00 a.m. on Tuesday, April 14, 2020 and end at 12: 00 noon on Friday, April 17, 2020. Please refer to the Prospectus for details.

Save as disclosed above, all other information contained in the Prospectus and the Application Forms remains unchanged.

The Directors are of the view that all material information relevant to the Listing has been disclosed in the Prospectus. The Company confirms that there has been no significant change affecting any matter contained in the Prospectus and that no significant new matter has arisen which would require the issue of a supplemental prospectus under Rule 11.13 of the Listing Rules.

By order of the Board  
**Akeso, Inc.**  
**Dr. XIA Yu**  
*Chairwoman*

Hong Kong, Wednesday, April 15, 2020

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. XIA Yu as Chairman and executive Director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Mr. XIA Yu (Ph.D.) as executive Directors, Mr. LIN Lijun and Dr. ZHOU Yi as non-executive Directors, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive Directors.*